Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 22;13:1072634. doi: 10.3389/fonc.2023.1072634

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Qin, Xv, Chen, Wang, Lu, Li, Guo, Yang, Liu, Wang and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Network meta-analysis plots for outcomes of interest in intent-to-treat population and (B) Network meta-regression analysis plots for outcomes of interest in intent-to-treat population. Suni, Sunitinib; Bev, Bevacizumab; Cabo, Cabozantinib; Pazo, Pazopanib; Savo, Savolitinib; Sora, Sorafenib; Axi, Axitinib; Anlo, Anlotinib; Nivo, Nivolumab; Atezo, Atezolizumab; Pem_Axi, Pembrolizumab plus Axitinib; Atezo_Bev, Atezolizumab plus Bevacizumab; Ave_Axi, Avelumab plus Axitinib; Len_Pem, Lenvatinib plus Pembrolizumab; Nivo_Cabo, Nivolumab plus Cabozantinib; Nivo_Ipi, Nivolumab plus lpilimumab; Len_Evero, Lenvatinib plus Everolimus; Pazo_Evero, Pazopanib plus Everolimus; IMA901_Suni, IMA901 plus Sunitinib.